Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Betalutin |
| Synonyms | |
| Therapy Description |
Betalutin (177Lu Lilotomab Satetraxetan) is a murine anti-CD37 antibody in conjuation with isotope Lutetium-177, which may have anti-tumor activity (Blood 2014 124(21):3094). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Betalutin | 177Lu Lilotomab Satetraxetan|Tetulomab tetraxetan Lu-177 | CD37 Antibody 9 | Betalutin (177Lu Lilotomab Satetraxetan) is a murine anti-CD37 antibody in conjuation with isotope Lutetium-177, which may have anti-tumor activity (Blood 2014 124(21):3094). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT01796171 | Phase Ib/II | Lilotomab Betalutin Rituximab | A Phase I/II Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-01) | Completed | USA | TUR | SWE | POL | NOR | NLD | ITA | ISR | IRL | HUN | HRV | GBR | FRA | FIN | ESP | DNK | CZE | CHE | CAN | BEL | AUT | AUS | 2 |
| NCT02658968 | Phase I | Betalutin | Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05) | Completed | USA | ITA | GBR | ESP | DEU | 0 |